オミクロン株対応ワクチンの効能・効果、用法・用量の一部変更承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_27929.htmlThe evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
オミクロン株対応ワクチンの効能・効果、用法・用量の一部変更承認について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
This page announces the approval of partial changes to the efficacy, effects, usage, and dosage of Omicron variant-adapted vaccines by Japan's Ministry of Health, Labour and Welfare on September 12, 2022. Pfizer's "Comirnaty RTU" and Moderna's "Spikevax" vaccines have been approved for expanded use to include formulations containing mRNA encoding spike proteins of both the original strain and Omicron variant. Both vaccines are approved for booster immunization, with a minimum interval of 5 months between doses, though future shortening of this interval is being considered.
